August 29, 2026
Bonus Content: Gilead’s Bixlenvo Is Approved. Now the Switch Math Begins.
Dear Reader,
On a single afternoon, President Trump signed four executive orders aimed at bringing one American energy source back from the dead.
Most investors never read them.
I did.
And together, they lay out one of the most ambitious energy expansions America has attempted in decades.
There’s just one problem buried inside Trump’s plan:
Where is all the fuel going to come from?
Because America barely produces it anymore.
We consume roughly 50 million pounds a year…
Yet produce less than 2% of it here at home.
And you can’t simply create new supply overnight.
Which is why one tiny company in Wyoming caught my attention.
It controls more than 30 million pounds of the fuel Trump’s energy plan needs.
That’s more than the U.S. government holds in its entire Strategic Reserve of this material.
And Washington already knows about this company.
The federal government has bought from it directly.
Yet its stock still trades for around $1.50 a share.
And now I have one date circled:
November 4th.
That’s when a catalyst I’ve been tracking could put this little-known Wyoming company on a lot more investors’ radar.
See How to Get Trump’s Secret $1.50 Energy Mine
Yours in smart speculation,
Karim Rahemtulla
Co-Founder
Monument Trend Advisory
Gilead’s Bixlenvo Is Approved. Now the Switch Math Begins.
Hey there, bargain hunter. The regulatory risk is gone. The commercial risk is just getting started.
Scoreboard
The FDA approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) on August 27, on its PDUFA date, as the smallest once-daily single-tablet regimen for virologically suppressed adults with HIV. It is now the first and only single-tablet option for people on complex regimens who were unable to take currently available single-tablet regimens. The stock market had weeks to price this in. The question worth asking is whether it bothered.
What the Business Actually Looks Like
Gilead’s HIV franchise is not a side project. In 2025, HIV product sales were $20.8 billion. Total 2025 revenue was about $28.8 billion. Biktarvy generated about $13.4 billion in full-year 2025 sales, and second-quarter 2026 Biktarvy sales reached $3.8 billion, up about 7% from a year earlier. That one drug is the engine. Everything else is attached to it.
Bixlenvo pairs bictegravir, the active ingredient in Biktarvy, with lenacapavir, a capsid inhibitor with no cross-resistance to other antiretrovirals. Bixlenvo requires a two-day initiation dose with Sunlenca, thereafter only Bixlenvo is taken orally once a day. The molecule is the same; the pill is smaller and the combination is harder to replicate.
The Real Question: Switch Volumes vs. LOE Discount
The market has long punished Gilead for a fear that never quite arrives: the Biktarvy patent cliff. Lupin, Cipla, and Laurus Labs agreed to delay any generic version of Biktarvy until April 1, 2036. That is a decade away. Meanwhile, the HIV portfolio saw 12% growth in Q2 2026, supported by Biktarvy and PrEP performance above $1 billion in quarterly sales, prompting management to raise full-year HIV growth guidance to 9% to 10%.
Bixlenvo’s commercial opportunity sits inside the switch market. The approval introduces a treatment-switch option designed to maintain viral suppression while reducing pill burden for eligible patients, including some who have required complex multidrug regimens because of resistance, tolerability concerns, contraindications, or drug interactions. Switching to Bixlenvo in ARTISTRY-1 was associated with improvements in certain fasting lipid parameters and participant-reported treatment satisfaction. Physicians notice when patients feel better on a smaller pill. Payers notice the tab.
Data Section
- Biktarvy: about $13.4 billion in full-year 2025 sales
- HIV product sales: $5.0 billion in Q1 2026, up 10% year-over-year
- Yeztugo: $232 million in Q2 2026, up from $15 million in the prior-year period
- FY2025 adjusted gross margin near 87%; $9.5 billion of free cash flow generated
- Full-year 2026 product sales guidance: $30.1 billion to $30.4 billion
- Forward P/E: approximately 15x
- Analyst consensus: Buy, average price target about $158
Is It Cheap?
Priced at around 16x forward normalized EPS, with an EPS growth trajectory of roughly 5% to 13% annually through 2027, GILD appears undervalued against a pipeline inflection that includes up to 10 commercial launches through 2027, a Biktarvy patent runway extending to 2036, and free cash flow set to grow around 33% in 2026. The drug manufacturers industry median forward P/E sits at 16.85, and GILD trades roughly 10% below that median. You are getting a company with near-87% gross margins and a decade of Biktarvy exclusivity for less than the peer average multiple. Bixlenvo switch volumes are not in that price.
Bull / Base / Bear
Bull: Bixlenvo captures a meaningful share of the complex-regimen switch population within 18 months. Yeztugo continues toward $1 billion in annual prevention sales. Anito-cel in multiple myeloma, with an FDA decision due December 23, 2026, adds a third growth vector. The LOE discount disappears as 2036 clarity sinks in.
Base: Bixlenvo builds slowly, cannibalizing some Biktarvy scripts rather than expanding the addressable pool. HIV grows at the guided 9% to 10%. The stock grinds toward analyst targets without re-rating.
Bear: Bictegravir and lenacapavir in combination are not approved by any regulatory authority outside the United States, limiting Bixlenvo’s near-term revenue upside to one market. Payer friction slows switching. The 87% gross margin comes under pressure if Gilead discounts to drive adoption. Any pipeline stumble on anito-cel re-introduces a risk-off read on the whole name.
Action Plan
GILD at roughly 15x forward earnings, with a 2036 Biktarvy exclusivity floor and two freshly approved products (Bixlenvo and Yeztugo) in the same HIV franchise, is a buy-and-monitor situation, not a speculative swing. Gilead announced a cash dividend of $0.82 with an ex-date of September 15, 2026, which adds a concrete near-term return while the switch volumes build. Scale in on any broad market pullback that takes GILD down with it. Trim only if HIV guidance gets cut or Bixlenvo payer coverage stalls past Q1 2027.
Cheap Investor Scorecard
- Bixlenvo payer coverage: Track formulary wins quarterly. Target 80% coverage within 12 months of launch.
- Biktarvy quarterly run rate: Watch for Bixlenvo cannibalization. Net HIV revenue growth is the signal, not individual product lines.
- Yeztugo trajectory: Full-year 2026 guidance is $1 billion. A miss flags prevention uptake risk.
- Anito-cel FDA decision (Dec 23, 2026): Approval opens a third major revenue leg. Rejection removes a bull-case multiplier.
- Forward P/E vs. peer median: GILD closing the gap toward 17x to 18x is the re-rating signal to watch.
- Free cash flow growth: 2026 guidance implies a 33% step-up. If it comes in, the dividend has room to grow.
- International Bixlenvo filings: Watch for ex-U.S. regulatory submissions, which would materially expand the addressable market.
Bottom Line
If Bixlenvo converts even a fraction of the complex-regimen population and Yeztugo hits its $1 billion prevention target, Gilead is carrying more than one growth driver into 2027. The LOE fear is already priced in at 15x forward earnings. The switch volume upside is not. This is what a defensive multiple with a hidden catalyst looks like.
